Agilon Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Agilon Health, Inc. on February 12, 2026. The filing discloses the entry into a material definitive agreement involving the Company, its management entity, and its intermediate holding company regarding their credit facilities.
Key Financial Metrics and Debt Structure
The filing details amendments to the Company's Credit Agreement but does not report specific revenue, profit, or cash flow figures for the period. Key debt-related metrics disclosed include:
- Revolving Credit Commitments: Reduced from $100.0 million to $90.0 million.
- Minimum Cash Requirement: Management must maintain a minimum of $50 million in Total Cash as of the end of each business day.
- Letter of Credit Collateralization: Required at 103% of the outstanding amount immediately prior to the amendment.
- Guaranty: The Company executed an unsecured Parent Guaranty of Management's obligations under the Credit Agreement.
Material Changes Versus Prior Period
The Third Amendment to the Credit Agreement, effective February 12, 2026, introduced the following material changes to the existing terms:
- Maturity Extension: The stated maturity date was extended from February 18, 2026, to February 18, 2028.
- Covenant Adjustments: Certain covenant "baskets" were amended to be measured as a percentage of EBITDA rather than, or as an alternative to, Consolidated Total Assets.
- Dividend Restrictions: Payments, including dividends to Holdings, are now conditioned on the Company achieving positive EBITDA for two consecutive trailing four-quarter periods ending after the amendment date.
- Prepayment Requirement: Any reduction in outstanding letters of credit must be accompanied by a corresponding prepayment of term loans.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future performance, or a discussion of general risks beyond the specific covenants imposed by the amendment. The primary contingency noted is the requirement for positive EBITDA over two consecutive four-quarter periods to enable certain payments to the parent holding company.
Key Facts for Investor Verification
- Verify the Company's current Total Cash balance to ensure compliance with the new $50 million minimum requirement.
- Confirm the Company's EBITDA performance for the trailing four quarters to assess eligibility for future dividend payments.
- Review the full text of the Third Amendment (Exhibit 10.1) for detailed definitions of the new EBITDA-based covenant baskets.
- Monitor the status of outstanding letters of credit and the corresponding term loan prepayment obligations.